trastuzumab (Herceptin)

1.	Zielinski, Christoph C: 15 articles (10/2008 - 03/2004)
2.	Esteva, Francisco J: 15 articles (09/2008 - 04/2002)
3.	Altundag, Kadri: 11 articles (01/2008 - 01/2004)
4.	Aglietta, Massimo: 10 articles (08/2008 - 02/2003)
5.	Montemurro, Filippo: 10 articles (01/2008 - 02/2003)
6.	Slamon, Dennis J: 10 articles (05/2007 - 02/2002)
7.	Bartsch, Rupert: 8 articles (10/2008 - 07/2004)
8.	Wenzel, Catharina: 8 articles (10/2008 - 07/2004)
9.	Steger, Guenther G: 8 articles (10/2008 - 07/2004)
10.	Köstler, Wolfgang J: 8 articles (09/2008 - 03/2004)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 02/01/2009 - "CONCLUSIONS: Most studies presenting the frequently proposed threshold of QALY suggest that trastuzumab may be cost-effective for treatment of early breast cancer in a 1-year treatment regimen." 06/01/2002 - "Hopefully, information from these trials will help resolve questions regarding the efficacy of various combinations and dosing schedules so that trastuzumab may be used most effectively in the treatment of HER2-overexpressing breast cancer in both the metastatic and the adjuvant settings." 03/01/2002 - "In most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzumab." 09/01/2007 - "In the absence of randomized trials, the optimal duration of trastuzumab administration after achieving complete remission of metastatic breast cancer remains questionable." 07/01/2004 - "CONCLUSION: These studies suggest that (225)Ac-labeled trastuzumab may be a potent therapeutic agent against metastatic breast cancer cells exhibiting intermediate to high HER2/neu expression." Order ALL the reference details at left...
2.	Neoplasms (Cancer) 03/01/2006 - "In patients with HER2-positive tumors, trastuzumab has dramatically improved therapeutic results when added to standard adjuvant treatment. " 08/01/2005 - "Nevertheless, while trastuzumab is highly effective in many Her-2/neu overexpressing tumors, some do not respond. " 02/26/2004 - "Moreover, COX-2 enzymatic inhibition dramatically reduced HER-2 protein levels, efficiently increased the cancer cells sensitility to chemotherapeutic treatment and acted in synergy with HER-2 inhibitor, trastuzumab. " 08/01/1999 - "In vitro studies demonstrate that trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets. " 08/01/2004 - "The in vivo analysis revealed a marked decrease in tumor size with the Ad-mda7 + Herceptin combination (P < .05). " Order ALL the reference details at left...
3.	Neoplasm Metastasis (Metastasis) 04/01/2006 - "Trastuzumab is highly effective for the treatment of liver and lung metastasis in HER2 overexpressing patients, while it is apparently ineffective for treating or preventing BM. " 09/01/2006 - "Authors have speculated that this is due to improved systemic control of disease; however, a possibility is that trastuzumab may have a beneficial effect on cerebral metastases themselves. " 02/01/2006 - "These reports showed that even after short term follow up one year of Herceptin resulted in improved disease free, metastases free and overall survival. " 01/01/2006 - "Moreover, among patients who received trastuzumab as first line treatment, isolated brain metastases were the initial site of progression in 17% patients. " 04/01/2008 - "Several studies had analyzed if metastases in the brain during treatment with trastuzumab have increased in comparison with the pretrastuzumab era. " Order ALL the reference details at left...
4.	Carcinoma (Carcinomatosis) 01/01/2001 - "Thus, our study suggests that anti-HER2/neu therapy with Herceptin is beneficial for patients with aggressive salivary duct carcinoma." 09/01/2009 - "EDIAs are strongly cytotoxic on ErbB2-positive cells in vitro and in vivo and bind to an epitope different from that of Herceptin, a humanized anti-ErbB2 mAb effective in the therapy of breast carcinoma, but cardiotoxic in a high percentage of cases. " 09/01/2002 - "Further research is warranted on the possible association of HER2 expression with chemosensitivitiy in urothelial carcinoma as well as the efficacy of HER2-targeted therapies (such as trastuzumab) for patients with high-grade, muscle-invasive urothelial carcinoma of the bladder." 08/01/2009 - "Systemic treatment with monoclonal antibody (mAb) trastuzumab can be effective against HER2-positive systemic breast carcinoma but, like other therapies, is ineffective against CM. The goal of this study was to evaluate the therapeutic effect of alpha-particle emitting (211)At-labeled trastuzumab following intrathecal administration in a rat model of breast carcinoma CM. METHODS: Athymic rats were injected intrathecally with MCF-7/HER2-18 breast carcinoma cells through a surgically implanted indwelling intrathecal catheter. " 10/01/2007 - "Immunohistochemistry or FISH for HER2/neu have been widely performed in numerous institutions and provide the gold standard for the treatment of trastuzumab in patients with breast carcinoma. " Order ALL the reference details at left...
5.	Disease Progression 10/01/2004 - "The benefits noted with trastuzumab-containing regimens were documented in clinical trials where trastuzumab was given until disease progression. " 09/01/2004 - "MATERIALS AND METHODS: Eighteen patients with HRPC were recruited for this phase II trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented. " 04/01/2004 - "We conducted a retrospective case review study of women with HER2-positive MBC who continued to receive trastuzumab beyond disease progression. " 03/15/2004 - "PATIENTS AND METHODS: A total of 247 patients with documented disease progression received weekly intravenous trastuzumab in the extension study. " 03/15/2004 - "We conducted an extension study to this trial to obtain additional safety information and to provide trastuzumab following disease progression. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	trastuzumab (Herceptin)
2.	Paclitaxel (Taxol)
3.	Epidermal Growth Factor Receptor (EGF Receptor)
4.	docetaxel (Taxotere)
5.	lapatinib (GW572016)
6.	taxane
7.	capecitabine (Xeloda)
8.	vinorelbine (Navelbine)
9.	Protein-Tyrosine Kinases (Tyrosine Kinase)
10.	gemcitabine

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Adjuvant Chemotherapy
3.	Heterologous Transplantation (Xenotransplantation)
4.	Aftercare (After-Treatment)
5.	Neoadjuvant Therapy

Best Treatments:
Research Summary Report
on Breast Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3868 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>